Literature DB >> 21703971

Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences?

Xiang-Yu Zhao1, Ying-Jun Chang, Xiao-Jun Huang.   

Abstract

Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancy patients who lack an HLA-matched related or unrelated donor. Natural killer (NK) cells, a major cell type of the innate immune system, express surface receptors that regulate potent effector functions, such as cytolytic activity and the release of cytokines, and play a central role in the inflammatory response and immunoregulation. Conflicting results have been reported regarding the impact of NK cell alloreactivity on the outcome of haploidentical SCT in leukemic patients. This review summarizes the heterogeneous clinical results and explains the underlying mechanisms with respect to the reconstitution kinetics of NK cells and the interactions between NK cells and T cells.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21703971     DOI: 10.1016/j.bbmt.2011.05.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

Review 1.  T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.

Authors:  C Russell Cruz; Catherine M Bollard
Journal:  Haematologica       Date:  2015-06       Impact factor: 9.941

2.  Engineering haploidentical transplants.

Authors:  S Naik; H E Heslop
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

3.  GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.

Authors:  Mark D Bunting; Antiopi Varelias; Fernando Souza-Fonseca-Guimaraes; Iona S Schuster; Katie E Lineburg; Rachel D Kuns; Peter Fleming; Kelly R Locke; Nicholas D Huntington; Bruce R Blazar; Steven W Lane; Siok-Keen Tey; Kelli P A MacDonald; Mark J Smyth; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Blood       Date:  2016-12-07       Impact factor: 22.113

4.  Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood.

Authors:  Xing-Xing Yu; Ting-Ting Han; Ling-Ling Xu; Ying-Jun Chang; Xiao-Jun Huang; Xiang-Yu Zhao
Journal:  J Cell Mol Med       Date:  2018-03-25       Impact factor: 5.310

5.  Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts.

Authors:  Xuying Pei; Xiangyu Zhao; Yu Wang; Lanping Xu; Xiaohui Zhang; Kaiyan Liu; Yingjun Chang; Xiaojun Huang
Journal:  Front Med       Date:  2017-09-08       Impact factor: 4.592

6.  Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.

Authors:  Klaus Witter; Roland Reibke; Marion Subklewe; Robert Zahn; Teresa Kauke; Karsten Spiekermann; Michael Spannagl; Johanna Tischer; Wolfgang Hiddemann; Andrea Dick
Journal:  Bone Marrow Res       Date:  2014-04-03

Review 7.  Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.

Authors:  Anne M Dickinson; Jean Norden; Shuang Li; Ilona Hromadnikova; Christoph Schmid; Helga Schmetzer; Hans Jochem-Kolb
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

Review 8.  The Graft-Versus-Leukemia Effect in AML.

Authors:  Connor Sweeney; Paresh Vyas
Journal:  Front Oncol       Date:  2019-11-19       Impact factor: 6.244

9.  HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.

Authors:  X-Y Zhao; Y-J Chang; L-P Xu; X-H Zhang; K-Y Liu; D Li; X-J Huang
Journal:  Br J Cancer       Date:  2014-07-31       Impact factor: 7.640

10.  Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study.

Authors:  Zimin Sun; Huilan Liu; Chenhui Luo; Liangquan Geng; Changcheng Zheng; Baolin Tang; Xiaoyu Zhu; Juan Tong; Xingbing Wang; Kaiyang Ding; Xiang Wan; Lei Zhang; Wen Yao; Kaiding Song; Xuhan Zhang; Yue Wu; Huizhi Yang; Yongsheng Han; Xin Liu; Weibo Zhu; Jingsheng Wu; Zuyi Wang
Journal:  Int J Cancer       Date:  2018-03-12       Impact factor: 7.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.